Home About Us Services Markets Resarch Online Trading Back Office Contact Us Download Mutual Fund
Your are on :  Markets   |  News Analysis    |  Stock Alert   |Detailed News   
Back
Stock Alert: Alembic Pharma, Bajel Projects, Zydus Lifesciences, Lupin, Adani Enterprises, Biocon
30-Sep-24   08:34 Hrs IST

Stocks to watch:

Alembic Pharmaceuticals' oral solid formulation facility (F-1) located in Panelav, Gujarat received establishment inspection report (EIR) from United States Food and Drug Administration (USFDA), which was inspected by USFDA from 17 July to 26 July 2024.

Bajel Projects had successfully entered the emerging data centre segment by securing its first order from an upcoming data centre service provider. The order involves the design and construction of a 220/33kV gas-insulated switchgear (GIS) substation and transmission line extension for a colocation data centre in Navi Mumbai, Maharashtra.

Zydus Lifesciences received final approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Capsules, 40 mg.

Lupin's Pithampur facility in Madhya Pradesh, which includes the unit-1 API and finished product manufacturing site, has completed the U.S. Food and Drug Administration (USFDA) inspection with 3 observations.

Adani Enterprises' unit April Moon will acquire a 74% stake in Cococart Ventures for Rs 200 crore.

Adani Energy Solutions has signed a business transfer agreement with its subsidiary, North Maharashtra Power to carve out the Adani Dahanu Thermal Power Station. Adani Electricity Mumbai is a subsidiary of the company.

IndusInd Bank's board has approved the re-apppointment of Sumant Kathpali as managing director & chief executive officer (CEO) for a term of three years, effective from 24 March 2025.This re-appointment is subject to approval by the reserve bank of India and bank's shareholder.

Biocon's API facility (Site 2) in Bengaluru was inspected by US Food and Drug Administration (USFDA), from 23 September to 27 September 2024 ended with four observations.

Powered by Capital Market - Live News

Product Disclaimer Mandatory Information Privacy Policy Careers Risk disclosures Feedback Scores 2.0 Member Bank Details
"Investor Grievance" Mail your Grievance to info@lalkar.in
Important Links:   SEBI  |  NSE  |  BSE  |  MCX-SX  |  MCX   |   NCDEX  |  NSDL  |  CDSL  |  FMC   |   CDSL E-Voting  |  SMART ODR|  Saa₹thi  |  View Client Collateral Details
SEBI REGISTRATION NOS - BSE CASH: INZ000269434  |  BSE FNO: INZ000269434  |  NSE CASH: INZ000269434  |  NSE FNO: INZ000269434  |  NSE CD: INZ000269434  |  MSEI CASH: INZ000269434   |   MSEI FNO: INZ000269434   |   MSEI CD: INZ000269434
AMFI NO : ARN- 19226  |  LALKAR COMMODITIES PVT. LTD.: MCX: 10685 FMC: MCX/TCM/CORP/0655 | NSEL: 11300 | NCDEX: 1130 FMC No : NCDEX/TCM/CORP/1106
2010 © Lalkar Group. All rights reserved Designed, developed & powered by CMOTS Infotech(ISO 9001:2015 certified)